Chloroform
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Chloroform
Chloroform: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Chloroform, so there is currently no new predicted indication. The uses recorded for this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 0 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 187W | nan | nan | Valid |
Safety Considerations
Safety information specific to Australia was not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Based on the retrieved literature and general toxicology knowledge, chloroform:
- Causes CNS and respiratory depression, and delayed hepatotoxicity after ingestion
- Is nephrotoxic and cardiotoxic, sensitising the myocardium to catecholamines and potentially causing arrhythmias
- Is a probable carcinogen and a suspected developmental toxicant
- Suppressed lung host defences in mice after inhalation (PMID 20925451)
No drug interaction data were found.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.